

Immix Biopharma

Fleshing out the CAR-T strategy

Q225 results

Immix has published its **Q225 results**, reflecting a productive period for NXC-201. The US-based NEXICART-2 trial in relapsed/refractory amyloid light chain amyloidosis (r/r ALA) reported an encouraging interim update and, given the current pace, Immix maintains its plans to file for regulatory approval once the trial concludes in mid-2026. Management also announced the potential expansion of NXC-201 into additional indications, which could increase the value proposition for the candidate. The company ended Q225 with net cash of \$11.64m, which was bolstered post period by a further \$1.34m through an at-the-market (ATM) offering. We estimate that this should provide a cash runway into Q126, but note the potential for this to extend should further proceeds be raised through the ATM facility. Following the Q225 results, our valuation for Immix stands at \$126.8m, or \$4.3 per share (from \$127.0m, or \$4.6/share previously).

Year end	Revenue (\$m)	PBT (\$m)	EPS (\$)	DPS (\$)	P/E (x)	Yield (%)
12/23	0.0	(13.0)	(0.75)	0.00	N/A	N/A
12/24	0.0	(18.6)	(0.66)	0.00	N/A	N/A
12/25e	0.0	(18.8)	(0.62)	0.00	N/A	N/A
12/26e	0.0	(25.7)	(0.82)	0.00	N/A	N/A

Note: PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

NXC-201 set to expand to additional indications

In early August, Immix **announced** its strategy to expand the application of NXC-201 to multiple other serious diseases. While precise disease targets are yet to be disclosed, we believe they are likely to focus on autoimmune indications, where interest has previously been expressed. According to management, these other programmes target a \$25bn combined annual market size (per estimates from Grand View Research and Fortune Business Insights). Immix is due to present details, including clinical data, at upcoming scientific forums and will preferentially seek to explore out-licensing opportunities for these other serious diseases (it plans to retain rights in ALA). Should NXC-201 demonstrate efficacy in these other serious diseases, it could maximise the commercial potential of the candidate.

NEXICART-2 readouts remain encouraging

NEXICART-2 trial's interim readouts have been highly promising, in our view, with the most recent **update** at the 2025 American Society of Clinical Oncology (ASCO) meeting. The data showed a complete response rate of 70% (seven of 10 patients). Immix has continued to **communicate** to the market that NXC-201 has a favourable safety profile, with no cases of neurotoxicity and only low-duration cases of cytokine release syndrome. This should position NXC-201 as a potential outpatient CAR-T therapy, offering notable differentiation and potential for improved accessibility compared to current approved CAR-T therapies. It is this favourable safety profile that supports the possibility of expanding NXC-201 to other serious diseases.

Valuation: \$126.8m or \$4.3 per share

Our valuation shifts to \$126.8m, or \$4.3 per share (from \$127.0m, or \$4.6/share), with the lower net cash position and higher number of shares outstanding being the cause for the subtle decrease. We make no changes to our long-term assumptions.

Healthcare

19 August 2025

Price	\$2.39
Market cap	\$70m
Pro forma net cash at 30 June 2025 (including post-period proceeds from ATM facility announced in June)	\$13.0m
Shares in issue (including additional shares issued post-period from ATM facility)	29.3m
Free float	60.0%
Code	IMMX
Primary exchange	NASDAQ
Secondary exchange	N/A

Share price performance



%	1m	3m	12m
Abs	(10.2)	10.6	19.5
52-week high/low		\$3.2	\$1.3

Business description

Immix Biopharma is a clinical-stage biopharma company developing personalised therapies for oncology and immunology. Lead asset NXC-201 is a BCMA-targeting CAR-T asset, being evaluated for amyloid light chain amyloidosis with plans to expand to autoimmune indications. A Phase I/II trial, NEXICART-2, is ongoing in the US, with top-line results expected in mid-CY26. The company is also seeking strategic options for legacy asset IMX-110, targeting solid tumors.

Next events

NXC-201 update (additional indications)	H225
NEXICART-2 conclusion	Mid-2026

Analysts

Jyoti Prakash, CFA	+44 (0)20 3077 5700
Arron Aatkar, PhD	+44 (0)20 3077 5700

healthcare@edisongroup.com
[Edison profile page](#)

Immix Biopharma is a research client of Edison Investment Research Limited

Pipeline led by programme focused on NXC-201 in r/r ALA

NXC-201 is a sterically-optimised B-cell maturation antigen (BCMA) targeting chimeric antigen receptor T (CAR-T) cell therapy. The current strategic priority for Immix is the NEXICART-2 trial, assessing NXC-201 in patients with r/r ALA, a debilitating condition that lacks effective and durable treatment options. NEXICART-2 is a US-based, open-label, single-arm, multi-site dose escalation/expansion Phase Ib/II trial, aiming to treat 40 r/r ALA patients, after which management plans to submit a biologics licence application to the FDA. The trial aims to build on the encouraging results of the Israel-based NEXICART-1 trial.

Exhibit 1: Immix's clinical development pipeline

Indication	Therapy	Pre-clinical	Phase 1	Phase 2	Upcoming Milestones
Relapsed/Refractory AL Amyloidosis	NXC-201	US FDA and EU EC Orphan Drug Designation (ODD)			<div>✓ 2Q 2025: Report interim clinical data readout for NEXICART-2 trial in relapsed/refractory AL Amyloidosis</div> <div>4Q 2025 / 1Q 2026: Planned NEXICART-2 enrollment completion</div> <div>2Q/3Q 2026: Report final topline clinical data readout for NEXICART-2 trial in AL Amyloidosis</div>
Undisclosed select Other Serious Diseases	NXC-201	IND enabled			2Q 2026: Report NXC-201 interim clinical data in unaddressed immune-mediated diseases
Other Emerging Pipeline					
Preclinical Candidates	Not yet announced				


Source: Immix Biopharma

The latest NEXICART-2 [update](#) corresponded to the first 10 patients from the trial. As of the data cut-off of 11 April 2025, a complete response (CR) rate of 70% was reported, whereby a CR was observed in seven of 10 patients (Exhibit 2). Furthermore, the remaining three patients were classified as being minimum residual disease negative, meaning that no diseased cells were found when testing one million bone marrow cells. From a safety perspective, NXC-201 is maintaining its track record of showing zero cases of neurotoxicity and only early onset and short-lived cases of cytokine release syndrome. This provides promise for NXC-201 to become the first 'outpatient' CAR-T therapy, with potential to offer improved accessibility compared to current available CAR-Ts. An independent review committee determined that the primary efficacy endpoint was met (at the interim stage) based on the CR rate of these first 10 patients, which management noted will advance progress towards submitting a biologics licence application for FDA approval. Patient enrolment is progressing as planned (total expected n=40) and we anticipate trial conclusion in mid-2026.

ALA is a debilitating and often fatal condition, characterised by progressive organ dysfunction. It is a rare disease (c 33k estimated cases in the US) for which NXC-201 has been granted orphan drug designation by the [FDA](#) and [EMA](#), offering seven and 10 years of market exclusivity in the US and EU, respectively, provided it is successful with regulatory approval. The first-line treatment for ALA is a four-drug combination of daratumumab with bortezomib, cyclophosphamide and dexamethasone. However, many patients do not respond to this treatment and relapse represents an ongoing medical dilemma. Autologous stem cell transplantation offers the potential for durable responses, but only a small portion of r/r ALA patients are fit enough for this treatment, and those who do undergo it face an extended recovery time. There is, therefore, an [unmet need](#) for this patient population, which Immix aims to address. To our knowledge, NXC-201 is the only CAR-T therapy in development for ALA.

Companies developing and commercialising CAR-Ts had previously faced headwinds due to FDA requirements for black box warnings due to risks of secondary malignancies. However, the FDA has [recently communicated](#) that the benefits of such products outweigh the risks, marking a key step forward for the field. In our view, with NXC-201's favourable safety profile, it is well positioned to address unmet needs in this field, with the option to expand its application to other serious diseases representing a potentially sizeable opportunity.

Exhibit 2: NEXICART-2 data showed complete responses in seven of 10 r/r ALA patients



Source: Immix Biopharma corporate presentation

Financials and valuation

Immix reported an operating loss of \$6.72m for Q225, reflecting a 43% increase on both a year-on-year basis and on a quarterly basis (operating losses of \$4.7m in both Q224 and in Q125). This difference is solely due to an increase in R&D-related expenses in the last quarter, which came in at \$4.0m (versus \$2.0m in Q125). The increase in R&D expenses was driven by an increase in expenses related to the ongoing NEXICART-2 trial, which has picked up in pace across the past few months. Immix is entitled to \$8m in reimbursements from the California Institute for Regenerative Medicine (CIRM) through a July 2024 [grant](#). While it received \$1.7m in Q125 and \$1.9m in Q424, offsetting its R&D expenses for these prior periods, no reimbursements were received in Q225. We expect the remaining \$4.4m to be realised during H225. General and administrative (G&A) expenses for the quarter were \$2.7m, consistent with the corresponding Q125 figure. G&A costs were mainly attributable to salaries, patent maintenance costs, general accounting and other general consulting expenses. Cash burn increased over twofold compared to the prior quarter, with cash flow from operations coming in at \$5.3m (versus \$1.7m in Q125), but relatively in line on a year-on-year basis (cash flow from operations was \$5.3m in Q224).

Following Immix's Q225 results, we have made only minor adjustments to our FY25 R&D estimates. Based on the latest figures, we increase the estimate to \$10.9m, from \$8.9m previously. All other near-term and long-term assumptions remain unchanged since the release of the company's FY24 report. A more detailed breakdown of these can be found in our [prior update note](#). As expected, the NEXICART-2 trial remains Immix's strategic priority, and it has made encouraging headway in the last quarter with the announcement of positive data and complete response rates, as presented at ASCO 2025. We also look forward to subsequent announcements regarding the expansion of NXC-201 to other serious diseases. For now, our operating loss estimates for FY25 and FY26 stand at \$22.9m and \$27.5m, respectively.

Immix ended Q225 with a net cash position of \$11.6m. This was bolstered post period by \$1.4m through the company's [ATM offering](#) (announced in June 2025), giving a pro forma cash position of \$13.0m. Based on our projected cash burn rates, and assuming all remaining proceeds from the CIRM grant are realised in H225, we estimate that Immix has a cash runway into Q126. This is more conservative than management's guidance of a cash runway into Q326. However, we note that our estimate does not account for additional proceeds that may come from the ATM facility, which, if realised, will provide additional operational headroom. The ATM facility allows the issuance of up to \$50m of common stock and, to date, \$2.4m has been issued. \$1.1m of this was within the reporting period, while \$1.3m was issued post-period, in August 2025.

Reflecting the above, our valuation for Immix remains relatively unchanged at \$126.8m, or \$4.3 per share (from \$127.0m, or \$4.6 per share previously). The slight decrease is caused by the lower net cash position and the per-share

valuation is further affected by the higher number of shares outstanding, following the additional shares issued from the ATM facility. Exhibit 3 presents a breakdown of our valuation.

Exhibit 3: Immix's risk-adjusted net present value

Product	Indication	Launch	Peak	Peak sales (US\$m)	Value (US\$m)	Probability	rNPV (US\$m)	rNPV/ share (US\$)
NXC-201	AL Amyloidosis	2028	2034	520.1	313.4	30%	94.0	3.2
IMX-110	STS	2031	2036	426.9	117.5	8%	8.8	0.3
IMX-110	Solid Tumours	2031	2036	425.3	146.9	8%	11.0	0.4
Pro-forma net cash at 30 June 2025 (including post-period proceeds from the ATM facility)					13.0	100%	13.0	0.4
Valuation					590.7		126.8	4.3

Source: Edison Investment Research

As noted above, we estimate that the company currently has sufficient operational headroom into Q126. However, we acknowledge that this does not account for additional proceeds from the ATM facility and management's guidance of a runway to Q326 is likely to include these proceeds. We forecast that Immix will need to raise \$25m in 2026, prior to signing a partnership deal for NXC-201 in 2027. Should a licensing deal not materialise, we estimate that Immix would be required to raise an additional \$15m in 2027, before turning cash flow positive during 2028 and after the potential commercial launch of NXC-201 in ALA. We reflect these capital raises as illustrative debt in our model. Should these funds (a total of \$40m across 2025–27) be raised through an equity issuance, Immix would need to issue 16.7m shares (based on the current share price of \$2.39), which would decrease our per-share valuation to \$3.6 (from \$4.3 per share currently). The number of shares outstanding would increase to 46.1m (from 29.3m currently).

Exhibit 4: Financial summary

Accounts: IFRS; year end 31 December; US\$000s	2022	2023	2024	2025e	2026e
PROFIT & LOSS					
Total revenues	0	0	0	0	0
Cost of sales	0	0	0	0	0
Gross profit	0	0	0	0	0
Total operating expenses	(8,219)	(16,141)	(22,675)	(22,876)	(27,549)
Research and development expenses	(4,196)	(8,735)	(11,293)	(10,925)	(15,000)
SG&A	(4,023)	(7,406)	(11,382)	(11,951)	(12,549)
EBITDA (normalised)	(8,217)	(16,136)	(22,642)	(22,702)	(27,392)
Operating income (reported)	(8,219)	(16,141)	(22,675)	(22,876)	(27,549)
Finance income/(expense)	(0)	572	1,017	1,027	(1,196)
Exceptionals and adjustments	0	0	0	0	0
Profit before tax (reported)	(8,219)	(15,569)	(21,657)	(21,849)	(28,744)
Profit before tax (normalised)	(7,595)	(13,003)	(18,637)	(18,828)	(25,724)
Income tax expense (includes exceptionals)	(10)	(26)	(41)	(41)	(54)
Net income (reported)	(8,230)	(15,596)	(21,698)	(21,890)	(28,799)
Net income (normalised)	(7,606)	(13,030)	(18,678)	(18,870)	(25,778)
Basic average number of shares, m	13.9	17.3	28.3	30.4	31.2
Basic EPS (US\$)	(0.59)	(0.90)	(0.77)	(0.72)	(0.92)
Adjusted EPS (US\$)	(0.55)	(0.75)	(0.66)	(0.62)	(0.82)
Dividend per share (US\$)	0.00	0.00	0.00	0.00	0.00
BALANCE SHEET					
Property, plant and equipment	4	50	1,740	1,566	1,410
Other non-current assets	7	87	20	20	20
Total non-current assets	10	137	1,761	1,587	1,430
Cash and equivalents	13,437	17,510	17,682	933	955
Current tax receivables	256	1,172	1,974	1,974	1,974
Other current assets	1,205	1,106	542	1,106	542
Total current assets	14,898	19,788	20,198	4,013	3,471
Other non-current liabilities	475	0	0	0	0
Long-term debt	0	0	0	0	25,000
Total non-current liabilities	475	0	0	0	25,000
Accounts payable	1,273	3,722	8,622	8,622	8,622
Other current liabilities	0	0	0	0	0
Total current liabilities	1,273	3,722	8,622	8,622	8,622
Equity attributable to company	13,160	16,203	13,251	(3,188)	(28,966)
CASH FLOW STATEMENT					
Net income	(8,230)	(15,596)	(21,698)	(21,890)	(28,799)
Depreciation and amortisation	2	5	33	174	157
Share-based payments	624	2,566	3,021	3,021	3,021
Other adjustments	0	0	82	80	80
Movements in working capital	195	1,653	3,967	(564)	564
Cash from operations (CFO)	(7,408)	(11,371)	(14,595)	(19,180)	(24,977)
Capex	0	(52)	(1,178)	0	0
Acquisitions & disposals net	0	0	0	0	0
Other investing activities	0	0	0	0	0
Cash used in investing activities (CFIA)	0	(52)	(1,178)	0	0
Capital changes	2,914	15,521	15,946	2,431	0
Debt Changes	0	0	0	0	25,000
Other financing activities	318	(57)	2	0	0
Cash from financing activities (CFF)	3,232	15,464	15,949	2,431	25,000
Cash and equivalents at beginning of period	17,644	13,437	17,510	17,682	933
Increase/(decrease) in cash and equivalents	(4,176)	4,040	176	(16,749)	23
Effect of FX on cash and equivalents	(32)	33	(4)	0	0
Cash and equivalents at end of period	13,437	17,510	17,682	933	955
Net (debt)/cash	13,437	17,510	17,682	933	(24,045)

Source: Company accounts, Edison Investment Research

General disclaimer and copyright

This report has been commissioned by Immix Biopharma and prepared and issued by Edison, in consideration of a fee payable by Immix Biopharma. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out of or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright 2025 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.